AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, reported positive interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa (XLRP). The results show that patients treated centrally with its product candidate demonstrated durable improvement in visual function six months after dosing. These data reinforce the promising efficacy and safety results reported in September 2019 and will help to design the XLRP pivotal trial that is currently being planned to initiate by the end of 2020. The company also remains on track to report interim six-month data from the dose-escalation cohorts of both of its ongoing trials in achromatopsia.
“These promising results further demonstrate that our XLRP candidate has tremendous potential to provide a meaningful benefit to XLRP patients who today have no treatment options,” said Sue Washer, President and CEO of AGTC. “The positive results observed to date give us confidence that the data as a whole will support the advancement of our XLRP clinical program to a pivotal trial in 2020.”
Learn more about AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa.Related news:
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study. AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials. AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone.